Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 10/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 10/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 4/20 | 0.37 |
| ▸ | TNKS | O95271 | 3/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.37 |
| ▸ | QDPR | P09417 | 1/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.37 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14741074 | 0.89 | TLR9 (0.42) | TLR9TLR7TLR8PARP1TNKS | |
| SCHEMBL14741031 | 0.80 | TLR9 (0.43) | TLR9TLR7TLR8 | |
| SCHEMBL14745803 | 0.79 | DCTPP1 (0.40) | TLR9TLR7LMNAGAAMAPT | |
| SCHEMBL14745449 | 0.78 | GAA (0.38) | TLR9TLR7LMNAGAAMAPT | |
| SCHEMBL16428749 | 0.77 | NOTUM (0.39) | TLR9TLR7LMNAGAAMAPT | |
| SCHEMBL14745164 | 0.76 | KCNH2 (0.37) | TLR9TLR7LMNAGAAMAPT | |
| SCHEMBL16568432 | 0.76 | TLR9 (0.47) | TLR9TLR7TLR8PARP1TNKS | |
| SCHEMBL14744922 | 0.75 | PARP1 (0.38) | LMNAGAAMAPTPARP1 | |
| SCHEMBL16441003 | 0.74 | S1PR1 (0.33) | TLR9TLR7LMNAGAAMAPT | |
| SCHEMBL14745380 | 0.73 | QDPR (0.41) | TLR9TLR7LMNAGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9650395-B2 | Antibacterial compounds and methods for use | PTC THERAPEUTICS, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-20150080362-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080362-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | MRPL21, SLC11A2, CLPP | TLR9 392/4885TLR7 702/4885LMNA 2119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.